February 14, 2020
- Contera Pharma is preparing for public offering in KOSDAQ -
Bukwang has recently received the investigational new drug...
January 31, 2020
- Kalbe International to take on sales in 2 approved countries
Bukwang Pharmaceutical Co., Ltd (Bukwang) announced that i...
January 10, 2020
Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 s...
January 2, 2020
Bukwang Pharmaceutical announced that it has entered into an agreement with Sanofi-Aventis Korea to co-promote an ARB cl...
November 13, 2019
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseas...
September 30, 2019
ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up...
July 25, 2019
Dr Jean Bousquet, a renowned expert in pulmonary allergy, has delivered a keynote lecture on the next generation guideli...
July 10, 2019
3 million dollars invested by Medici Investment
European Clinical phase 2 study of JM-010 to treat dyskinesia i...
July 5, 2019
The sales of Dexid for diabetic polyneuropathy, Legalon for liver disease, and Entecavir for chronic hepatitis B are boo...
July 3, 2019
The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based B...
Older Posts >
Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND
Bukwang Initiates Exportation of its
In-House-Developed Drug, DEXIDⓇ to Southeast Asia
Bukwang initiates dosing of JM-010 in Europe phase 2 study
Bukwang Pharmaceutical has entered into co-promotion agreement with Sanofi- Aventis Korea on AprovelⓇ product family
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES
Bukwang Pharmaceutical hosted a keynote lecture by a renowned expert in pulmonary allergy
Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment
Bukwang’s representative ethical products outperformed
University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease.